Product Visual Guide
|
|
|
- Milton Watkins
- 6 years ago
- Views:
Transcription
1 Product Visual Guide
2 Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor. Accountability To be answerable is one of the keys to achieve the trust and respect from our customers. Righteousness and truthfulness are at the core of our work philosophy. Integrity OUR VALUES Standing on these four pillars, our company aims to be the most trusted company among healthcare professional and institutions in cancer care.
3 PRODUCTS FOR SOLID TUMORS I-DOX (Doxorubicin Hydrochloride Liposome Injection) As Pegylated Liposome 20mg/10ml 50mg/25ml Store between 2-8 C (36-46 F) in a refrigerator. Do not freeze. Metastatic Carcinoma of the Ovary whose disease has progressed or recurred after platinum-based chemotherapy Metastatic Breast Cancer patients with increased cardiac risk In combination with bortezomib for patients with Multiple Myeloma TAXE-RTU (Docetaxel Injection) One Vial Formulation 20mg/ml 80mg/4ml 120mg/6ml Store at a temperature not exceeding 25 C (77 F). Protect from light. Hormone Refractory Prostate Cancer (HRPC) Metastatic Breast Cancer NSCLC TAXEWELL (Docetaxel Injection Concentrate with Solvent) 20mg / 0.5ml 80mg / 2ml 120mg / 3ml Single use vial Single use vial Single use vial + Solvent in a combipack Store under refrigeration between 2-8 C (36-46 F). Protect from light. Hormone Refractory Prostate Cancer (HRPC) Metastatic Breast Cancer NSCLC 1
4 PRODUCTS FOR SOLID TUMORS PACLIWEL (Paclitaxel Injection) 30mg / 5ml 100mg / 16.7ml 260mg / 43.4ml 300mg / 50ml Multi Dose Vial Multi Dose Vial Multi Dose Vial Multi Dose Vial Store between C (68-77 F). Protect from light. Retain in carton until use. For the treatment of advanced carcinoma of the ovary For the adjuvant treatment of node-positive breast cancer GEFTIWEL (Gefitinib Tablets) 250mg Beige coloured, capsule shape film coated tablets 3x10 Tablets Store below 30 C (86 F). Protect from light and moisture. For locally advanced or metastatic NSCLC PEMETRA (Pemetrexed for Injection) 100mg 500 mg Store between C (68-77 F); Excursions permitted from C (59-86 F). For advanced nonsquamous non-small cell lung cancer (NSCLC), after prior chemotherapy In malignant pleural mesothelioma along with cisplatin, when surgery is not an option 2
5 PRODUCTS FOR SOLID TUMORS GEMWEL (Gemcitabine for Injection) 200mg 1gm Store between C (68-77 F); Excursions permitted from C (59-86 F). In relapsed advanced ovarian cancer in combination with Carboplatin In metastatic breast cancer patients after failure of prior anthracycline containing adjuvant therapy For inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer In locally advanced or metastatic Adenocarcinoma of the pancreas CISWEL (Cisplatin Injection) 10mg/10ml 50mg/50ml Store between C (59-77 F). Protect from light. Do not freeze. For metastatic testicular tumors, ovarian tumors & bladder cancer TEMZOL (Temozolomide Capsules) 20mg 100mg 250mg Yellow coloured hard gelatin capsules Sky Blue coloured hard gelatin capsules White coloured hard gelatin capsules 1x5 Capsules 1x5 Capsules 1x5 Capsules Store between C (68-77 F). Protect from light and moisture. In newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as a maintenance treatment In Refractory anaplastic astrocytomas 3
6 PRODUCTS FOR SOLID TUMORS TEMZOL (Temozolomide for Injection) 100mg Store under refrigeration between 2-8 C (36-46 F). Do not freeze. In newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment In Refractory anaplastic astrocytomas RINOWEL (Irinotecan Hydrochloride Injection) 40mg/2ml 100mg/5ml Store between C (68-77 F). Protect from light. Retain in carton until use. In Metastatic Carcinoma of Colon & Rectum with 5-Fluorouracil and Leucovorin XYLOTIN (Oxaliplatin Injection) 50mg/25ml 100mg/50ml Store between C (68-77 F). Protect from light. Retain in carton until use. As an adjuvant treatment of stage III (Duke's C) colon cancer in patients who have undergone complete resection of the primary tumor In the treatment of advanced metastatic colorectal cancer 4
7 PRODUCTS FOR SOLID TUMORS EPIRUBA (Epirubicin Hydrochloride for Injection ) 10mg 50mg Store at controlled room temperature C (59-86 F). Protect from light. As a adjuvant therapy in patients with evidence of axillary node tumor involvement in primary breast cancer DOXORUBA (Doxorubicin HCl Injection) 10mg/5ml 50mg/25ml Store under refrigeration between 2-8 C (36-46 F). Protect from light. Carcinoma of the breast, lung, bladder, thyroid and also ovarian cancer Hodgkin's lymphoma and Non Hodgkin's lymphoma DOXORUBA (Doxorubicin Injection) 10mg 50mg Store between C (59-86 F). Protect from light. Carcinoma of the breast, lung, bladder, thyroid and also ovarian cancer Hodgkin's lymphoma and Non Hodgkin's lymphoma 5
8 PRODUCTS FOR SOLID TUMORS CABITA (Capecitabine Tablets) 500mg Beige coloured, capsule shaped film coated tablets 1 x10 Capsules Store below 30 C (86 F). Protect from light and moisture. Treatment of Adjuvant Colorectal Cancer and Metastatic Breast Cancer FOSFA (Ifosfamide for Injection with Mesna Injection) 1gm 2gm 3gm Store below 25 C (77 F). Avoid extended exposure to temperature above 30 C (86 F). In Soft tissue sarcoma In advanced or recurrent cervical carcinoma Mesna Injection Strengths - 2ml, 4ml (Store in a cool and dark place) As a prophylatic agent in reducing the incidence of ifosfamide induced hemorrhagic cystitis ETOPA (Etoposide Capsules) 50mg 100mg Yellow coloured hard gelatin capsules Yellow coloured hard gelatin capsules 1x8 Capsules 1x8 Capsules Store below 25 C (77 F). Protect from light and moisture. Small cell lung cancer Testicular cancer Bladder cancer Hodgkin's lymphoma Non-Hodgkin's lymphoma 6
9 PRODUCTS FOR SOLID TUMORS ETOPA (Etoposide Injection) 100mg/5ml Store between C (68-77 F). Protect from light. Do not freeze. Small cell lung cancer Testicular cancer Bladder cancer Hodgkin's lymphoma Non-Hodgkin's lymphoma CYPHOS (Cyclophosphamide Injection) 200mg 500mg 1gm Store below 25 C (77 F). Avoid extended exposure to temperature above 30 C (86 F) Hodgkin's lymphoma, Lymphocytic lymphoma, Mixed cell type lymphoma, Histocytic lymphoma Multiple Myeloma Leukemias Carcinoma of breast TINOWEL (Dactinomycin for Injection) 0.5 mg Store between C (68-77 F). Protect from light. Wilm's tumor, childhood rhabdomyosarcoma, Ewing's Sarcoma and metastatic non-seminomatous testicular cancer For Palliative or adjunctive treatment of locally recurrent or locoregional solid malignancies 7
10 PRODUCTS FOR SOLID TUMORS CARBOWEL (Carboplatin Injection) 150mg/15ml 450mg/45ml Store between C (68-77 F). Protect from light. Do not freeze. For ovarian carcinoma in combination with Cyclophosphamide For the palliative treatment of patients with recurrent ovarian carcinoma 8
11 PRODUCTS FOR HEMATOLOGICAL MALIGNANCIES NEOMIB (Bor tezomib for Injection) 2mg 3.5 mg Store between C (68-77 F). Protect from light. Multiple Myeloma Mantle Cell Lymphoma who have received at least 1 prior therapy AZACITE (Azacitidine For Injection) 100mg Store between C (68-77 F); Excursion permitted from C (59-86 F). Used for treatment of French American British(FAB) myelodysplastic syndrome subtypes:refractory anemia(ra)or refractory anemia with ringed sideroblasts, refractory anemia with excess blasts(raeb), refractory anemia with excess blasts in transformation(raeb-t) and chronic myelomonocytic leukemia(cmmol) DECIMA (Decitabine Powder For Injection) 50mg Store between C (68-77 F); Excursion permitted from C (59-86 F). For the treatment of patients with Myelodysplastic syndrome (MDS) including previously treated and untreated, de novo and secondary MDS For the treatment of Acute Myeloid Leukemia (AML) 9
12 PRODUCTS FOR HEMATOLOGICAL MALIGNANCIES BLEOWEL (Bleomycin for Injection) 15 Units Store under refrigeration between 2-8 C (36-46 F). Squamous cell carcinoma Hodgkin s and non-hodgkin s Lymphoma Testicular carcinoma Malignant Pleural Effusion B E N D AW E L (Bendamustine Hydrochloride for Injection) 100mg Stored between C (68-77 F); Excursions permitted from C (59-86 F). Protect from light. In chronic lymphocytic leukemia In indolent B-cell non-hodgkin s lymphoma that has progressed during or within six months of treatment with rituximab MATNIB (Imatinib Mesylate Tablets) 100mg 400mg Brick Red coloured, capsule shape film coated tablets Beige coloured, capsule shape film coated tablets 1x10 Tablets 1x10 Tablets Store below 30 C (86 F). Protect from light and moisture. In Philadelphia chromosome positive myeloid leukemia For the treatment of Gastrointestinal Stromal Tumors (GIST) 10
13 PRODUCTS FOR HEMATOLOGICAL MALIGNANCIES L-GINASE (L-Asparaginase for Injection) 5000 I.U I.U. Store betwe en 2-8 C (36-46 F). Discard reconstituted solution wi thin 8 hours. As a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) THALIMIDE (Thalidomide Capsules) 50mg 100mg Light green coloured hard gelatin capsules Dark blue coloured hard gelatin capsules 3x10 Capsules 3x10 Capsules Store below 25 C (77 F). Protect from Light and moisture. Cutaneous manifestations of moderate to severe Erythema Nodosum Leprosum (ENL) Patients with newly diagnosed Multiple Myeloma in combination with Dexamethasone 11
14 PRODUCTS FOR SUPPORTIVE CARE ZOLDRON (Zoledronic Acid for Injection) 4mg Store between C (68-77 F). Protect from light. In hypercalcemia of malignancy For bone metastasis in patients with multiple myeloma and solid tumors LEUCOWEL (Leucovorin Calcium Injection) 15mg/2ml 50mg/5ml Store between 2-8 C (36-46 F). Do not freeze. Protect from light. After high dose Methotrexate therapy in osteosarcoma to diminish the toxicity caused by Methotrexate For use in combination with 5-fluorouracil to prolong survival in the palliative treatment patients with advanced colorectal cancer MEGETRA (Megestrol Acetate Tablets) 40 mg 160 mg White coloured, round, flat uncoated tablets White coloured, round, flat uncoated tablets 1 X 10 Tablets 1 X 10 Tablets Store below 25 C (77 F). Protect from light and moisture. In palliative treatment of advanced carcinomas especially for Anorexia Cachexia Syndrome 12
15 PRODUCTS FOR SUPPORTIVE CARE ULACTA (Urea & Lactic Acid Cream) Composition DESCRIPTION PACK SIZE Urea 12.0% w/w White coloured cream 75 gm Lactic acid 6.0% w/w in a round shaped jar Excipients q.s. Store below 25 C (77 F). Protect from light. For treating Hand and Foot Syndrome caused by various anti-cancer drugs Used for correction of hyperkeratosis and dryness in ichthyosis and allied conditions characterised by dry, rough, scaly skin GLUTAM -15 (L-Glutamine Oral Powder) Composition DESCRIPTION PACK SIZE L-Glutamine 10gm Fine graded Powder 5 Sachets x 15 gms Orange Flavour Excipients q.s. Store below 25 C (77 F). Protect from light and moisture. Decreases the incidence and severity of adverse effects due to radiation and chemotherapy in cancer patients such as: dermatitis, Stomatitis, Oesophagitis, intestinal permeability, Diarrhea DEXAM (Dexamethasone Tablets) 4mg 8mg Round white biconvex uncoated tablets Round white biconvex uncoated tablets 5x8 Tablets 5x8 Tablets Store below 25 C (77 F). Protect from light and moisture. For palliative management of Leukemias and Lymphomas in adults and acute leukemias of childhood As premedication in chemotherapy associated nausea and vomiting and taxane therapy 13
16 Getwell Group of Companies Getwell Pharmaceuticals Getwell Oncology Pvt. Ltd. Manufacturing Facility: 474, Udyog Vihar, Phase-V, Gurgaon , Haryana. INDIA Phone: /04 Corporate Office: 464, Udyog Vihar, Phase-V, Gurgaon , Haryana. INDIA Phone: /82
ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
Title Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
MEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
For Health Professionals Who Care For Cancer Patients
April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast
CLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
Avastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
Keytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.
Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
World Health Organization: Essential Medicines and Devices for Cancer:
World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health
An D. Nguyen, MD Curriculum Vitae
OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
For Health Professionals Who Care For Cancer Patients
March 2018 Volume 21, No. 3 For Health Professionals Who Care For Cancer s Inside This Issue: Editor s Choice New Programs: Nivolumab for Squamous Cell Cancer of the Head and Neck, Ibrutinib for Mantle-Cell
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
Guideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
The Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
For Health Professionals Who Care For Cancer Patients EDITOR S CHOICE
Inside This Issue: For Health Professionals Who Care For Cancer s March 2019 Vol. 22 No. 3 Editor s Choice New Programs: Rituximab Protocols in CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR,
Working Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
Summary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
The Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
Avastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)
CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)
Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
The legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
Avastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
CCC Chemotherapy Protocols V9.0
CCC Chemotherapy Protocols V9.0 General observations 3 Breast cancer 5 Gastrointestinal cancer Oesophagus 17 Gastric 19 Pancreas 22 Cholangiocarcinoma 24 Hepatocellular carcinoma 25 Neuroendocrine tumours
Lipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (docetaxel) Injection Concentrate,
MASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
General Authorization Criteria for ALL Agents and Indications:
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
Management of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
Drugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional
Drugs approved from 1st January 2015 till present S.NO Name Of Drug Indication Date of 1 Levocetirizine ODS 2.5mg /5mg dosage form) For allergic rhinitis and chronic urticaria. 14.01.15 2 Decitabine Injection
Haematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
Guidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
Essentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy
Practise Practise This tutorial introduces you to the history, goals of therapy, classification, and clinical uses of chemotherapy. It also reviews some of the barriers to successful therapy. Goals and
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
An introduction to the Essential Medicines concept: balancing innovation with public health priorities
An introduction to the Essential Medicines concept: balancing innovation with public health priorities WHO HQ, Geneva 11 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the Selection and
Macmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
Cancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.
PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES
ESMO Preceptorship GI Tumours Singapore 20-22 nd October CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES Professor. J-Y. Douillard MD PhD ESMO Chief Medical Officer CLINICAL PRACTICE GUIDELINES
The Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
Elements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Locally advanced or metastatic bladder cancer Bladder cancer is the sixth most common cancer. It is more common in men than in
American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.
American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG www.cancer.net www.cancer.net Tell your patients about the ASCO doctor-approved PATIENT INFORMATION WEBSITE Cancer.Net brings the
Policy. ( Number: *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB.
1 of 11 (https://www.aetna.com/) Number: 0889 Policy *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB. Aetna considers levoleucovorin (Fusilev) medically necessary for the following indications,
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
Open Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
Avastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)
Chemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
Advances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
Disease Site Sub-Disease Site Intent Regimen Code Regimen Details Status (as of October 17, 2017) Breast Not Applicable Adjuvant / Curative
ST-QBP Regimen Request Status for 2017/18 Below are status of regimen requests submitted for funding considerations in FY 17/18 Q1 & Q2. Requests with status will be updated on the ST-QBP website and will
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements
CLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
OPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
The Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
Erbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
DOSAGE FORMS AND STRENGTHS One vial docetaxel: Single use vials 20 mg/ml, 80 mg/4 ml and 160 mg/8 ml (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use docetaxel safely and effectively. See full prescribing information for docetaxel. Injection Concentrate,
It is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast